At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 140 enrolled
Drug / intervention
Levosimendan +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
The Effects of Levosimendan on Renal Function in Patients With Low Ejection Fraction Undergoing Mitral Valve Surgery.
Kartal Kosuyolu Yuksek Ihtisas Education and Research Hospital·interventional·Posted Oct 25, 2013·Updated Oct 25, 2013
In Brief
A Phase 4 clinical trial evaluating Levosimendan and Dobutamine for Mitral Valve Stenosis With Incompetence or Regurgitation. Completed, enrolled 140 participants across 1 site.
Detailed Summary
The effects of levosimendan on renal function in patients with low ejection fraction undergoing mitral valve surgery will be investigated in a prospective, double-blinded, randomized clinical trial using serum creatinine (sCr)milligram in deciliter (mg/dL) values, calculated estimated glomerular filtration(eGFR)(ml/min/1.73 m2) rates and perioperative clinical follow-up parameters.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesTurkey (Türkiye)
Collaborators--
Timeline
Phase 4CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartJul 2009
Primary CompletionJan 2013
Study CompletionSep 2013
First PostedOct 2013
TodayJul 2026
First PostedOct 25, 2013
Enrollment StartJul 1, 2009
Primary CompletionJan 1, 2013
Study CompletionSep 1, 2013
TodayJul 2, 2026
Enrollment to primary: 3.5 yearsPosted 12.7 years ago
Interventions
Levosimendandrug
The effects of levosimendan on renal function
Dobutaminedrug
Standard Inotropic agent